isabelobrien, Author at European Medical Journal - Page 39 of 68

AZ, GSK, Novartis, BMS and Sanofi lead Q2 2024 sales growth

The pharma industry shows strong growth into the second quarter of 2024, with companies reporting substantial YoY profit increases in Q2.

Elon Musk's Neuralink inserts brain implant into second patient

Elon Musk’s Neuralink has implanted its brain implant into a new patient, making them the second person to take part in the trial.

Taking control of customer experience

The team explores how the industry may be missing out on insights from HCPs and hears from Robert Tegge, Associate Principal, ZS, who shares valuable insights on congresses.

Spotlight: July 2024

Catch up on the top pharma news stories of July in EMJ GOLD’s monthly round-up, including insights on pharma’s use of social media.

Eli Lilly’s weight loss drug shows promise in heart failure

The weight loss drug reduces the risk of hospitalisation, death and more for adults with obesity and a common form of heart failure.

BMS boss reacts to soon-to-be-announced IRA prices

BMS has been a vocal opponent of drug price negotiations under the US’ Inflation Reduction Act, but a price preview may have allayed fears.

Labour government to allow researchers broader access to NHS data

Researchers and pharmaceutical companies could get wider access to NHS data for the first time under new Labour plans.

ViiV Healthcare’s Harmony Garges on giving voice to people with HIV

Dr Harmony Garges, Chief Medical Officer, ViiV Healthcare, discusses how best to serve patients of all ages living with HIV around the world.

Optimising pharma's customer experience journey

Customer experience is a key driver of product adoption in any industry – and this is no exception for the pharmaceutical realm.

WHO launches avian flu vaccine initiative for LMICs

With avian influenza posing an ongoing public health threat, a new initiative has been launched to better prepare low- and middle-income countries.